Premium
Association between CYP4F2 genotype and circulating plasma vitamin K concentration in children on chronic warfarin therapy: Possible long‐term implications for bone development and vascular health
Author(s) -
Kampouraki Emmanouela,
Avery Peter J.,
Biss Tina,
Kamali Farhad
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26653
Subject(s) - medicine , warfarin , osteocalcin , genotype , osteoporosis , matrix gla protein , vitamin , endocrinology , vitamin k , bone remodeling , vitamin k epoxide reductase , vitamin d and neurology , enzyme , cytochrome p450 , biochemistry , alkaline phosphatase , metabolism , biology , cyp2c9 , hyperphosphatemia , calcium , gene , atrial fibrillation
Vitamin K is essential, for the activation of clotting proteins, as well as the biosynthesis of osteocalcin in bones and the activation of matrix‐Gla protein needed in maintaining vasculature health. Cytochrome p450 4F2 (CYP4F2) enzyme is involved in vitamin K catabolism. Genetic polymorphism in CYP4F2 is thus likely to affect vitamin K systemic availability. We show that children on chronic warfarin therapy have low levels of vitamin K and vitamin K levels are linked to CYP4F2 genotype. Long‐term low levels of vitamin K, influenced by CYP4F2 genotype, might affect bone development and vascular health in children on chronic warfarin therapy.